Botanix announces regulatory approval of ECCLOCK® gel, 5% (Sofpironium Bromide) in South Korea

Botanix announced that Dongwha Pharm. Co., Ltd. has received regulatory approval for ECCLOCK® gel, 5% (Sofpironium Bromide) in South Korea. Dongwha is a sublicensee of Botanix’s Japanese partner, Kaken Pharmaceutical Co. Ltd.

Dongwha – Korea’s first and oldest pharmaceutical company – will commercialise ECCLOCK in the Korean market and add the product to its extensive range of prescription and over-the-counter products.